E-LIB Suche - Ergebnisse für: Fonteyne, V.

1

Moderate hypofractionated radiotherapy for prostate cancer:..:

Fonteyne, V. ; Berghen, C. ; Van Praet, C....
Radiotherapy and Oncology. 193 (2024) - p. 110089 , 2024

Link: https://doi.org/10.1016/..

2

The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 ques..:

Rammant, E. ; Fox, L. ; Beyer, K....
Quality of Life Research. 32 (2023) 8 - p. 2127-2135 , 2023

Link: https://doi.org/10.1007/..

3

Toxicity results of a multicentre randomized phase 3, non-i..:

Fonteyne, V. ; Berghen, C.B ; Van Praet, VC...
European Urology Open Science. 57 (2023) - p. S82-S83 , 2023

Link: https://doi.org/10.1016/..

4

Transcriptomic and clinical heterogeneity of metastatic dis..:

Sutera, P.A. ; Shetty, A.C. ; Hakansson, A....
Annals of Oncology. 34 (2023) 7 - p. 605-614 , 2023

Link: https://doi.org/10.1016/..

5

Transcriptomic Heterogeneity of Metastatic Disease Timing w..:

Sutera, P. ; Shetty, A. ; Hakansson, A....
International Journal of Radiation Oncology*Biology*Physics. 117 (2023) 2 - p. e261-e262 , 2023

Link: https://doi.org/10.1016/..

6

SP-0998 ESTRO-ACROP guideline on prostate bed delineation f..:

Dal Pra, A. ; Dirix, P. ; Khoo, V....
Radiotherapy and Oncology. 182 (2023) - p. S837 , 2023

Link: https://doi.org/10.1016/..

7

SP-0988 Optimal treatment of bladder cancer in the elderly ..:

Fonteyne, V.
Radiotherapy and Oncology. 182 (2023) - p. S833-S834 , 2023

Link: https://doi.org/10.1016/..

8

OC-0135 Predicting patient-reported symptom clusters in lun..:

Rammant, E. ; Deman, E. ; Poppe, L....
Radiotherapy and Oncology. 170 (2022) - p. S111-S112 , 2022

Link: https://doi.org/10.1016/..

9

Long-Term Outcomes and Genetic Predictors of Response to Me..:

Deek, M.P. ; Van der Eecken, K. ; Sutera, P....
International Journal of Radiation Oncology*Biology*Physics. 114 (2022) 3 - p. S22 , 2022

Link: https://doi.org/10.1016/..

10

OC-0603 PEACE V – STORM randomized phase II trial for oligo..:

Zilli, T. ; Siva, S. ; Heikkilä, R....
Radiotherapy and Oncology. 170 (2022) - p. S528-S529 , 2022

Link: https://doi.org/10.1016/..

11

The changing landscape of systemic therapy in the treatment..:

Lumen, N. ; Lambert, E. ; Fonteyne, V...
European Urology. 81 (2022) - p. S774-S775 , 2022

Link: https://doi.org/10.1016/..

12

Role of WNT Pathway Mutations within Oligometastatic Castra..:

Sutera, P. ; Van der Eecken, K. ; Deek, M.P....
International Journal of Radiation Oncology*Biology*Physics. 114 (2022) 3 - p. S158-S159 , 2022

Link: https://doi.org/10.1016/..

13

PEACE V – Salvage Treatment of OligoRecurrent nodal prostat..:

Ost, P. ; Siva, S. ; Heikkilä, R....
European Urology. 81 (2022) - p. S307-S308 , 2022

Link: https://doi.org/10.1016/..

14

Predicting patient-reported symptom clusters in prostate ca..:

Rammant, E. ; Deman, E. ; Poppe, L....
European Urology. 81 (2022) - p. S1687-S1688 , 2022

Link: https://doi.org/10.1016/..

15

PO-1378 Metastasis-directed therapy for oligorecurrent pros..:

Ost, P. ; Berlin, A. ; Siva, S....
Radiotherapy and Oncology. 161 (2021) - p. S1128 , 2021

Link: https://doi.org/10.1016/..